Shots:

• The 1st patient has been dosed in P-Ib/II (ADG116-1003) to evaluate the safety & tolerability of ADG106 (anti-CD137 agonist) + ADG116 (anti-CTLA-4 mAb) in patients with advanced/metastatic solid tumors at multiple sites in the US & Asia Pacific
• ADG106 & ADG116 as monothx. showed robust safety profiles & early signals of efficacy while ADG106 was well tolerated at doses of (3/5mg/kg) & 300/400mg flat doses with limited liver toxicity or hematologic abnormalities, a potential biomarker associated with tumor shrinkage was observed
• ADG116 showed a safety profile at doses of 10mg/kg in treatment-resistant tumors. The therapy achieved the recommended dose as monothx. & in combination

Ref: Globe Newswire | Image: Adagene